MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients.

ABSTRACT:

Introduction

Small molecules and antibodies are being developed to lower amyloid beta (Aβ) peptides.

Methods

We describe MEDI1814, a fully human high-affinity monoclonal antibody selective for Aβ₄₂, the pathogenic self-aggregating species of Aβ.

Results

MEDI1814 reduces free Aβ₄₂ without impacting Aβ₄₀ in the cerebrospinal fluid of rats and cynomolgus monkeys after systemic administration. MEDI1814 administration to patients with Alzheimer's disease (AD; n = 57) in single or repeat doses up to 1800 mg intravenously or 200 mg subcutaneously was associated with a favorable safety and tolerability profile. No cases of amyloid-related imaging abnormalities were observed. Predictable dose-proportional changes in serum exposures for MEDI1814

SUBMITTER: Lloyd C 

PROVIDER: S-EPMC11567870 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature